FN3-siRNA Conjugates for CD71-Mediated Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
SiRNA constructs face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular access when administered systemically, with existing delivery systems failing to efficiently target tissues other than the liver.
Innovation Solution
Conjugation of siRNA molecules with FN3 domains that specifically bind to CD71, allowing for receptor-mediated internalization and enhanced intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA is administered systemically as free siRNA, then it can reach intracellular compartment, but it is susceptible to nuclease digestion in plasma
Solution Approach 1:
The patent uses FN3 domains as intermediary proteins that bind to siRNA and protect it from nuclease digestion. These domains act as mediators between the siRNA and the cellular uptake machinery, shielding the siRNA from plasma nucleases while facilitating targeted delivery through CD71 receptor binding.
2Ease of operation
If lipid nanoparticles are used to deliver siRNA, then cellular uptake is facilitated, but efficient delivery to tissues other than liver is not achieved
Solution Approach 1:
The patent applies local quality by conjugating siRNA with FN3 domains that have specific binding affinity for CD71 receptors. This creates a localized targeting capability at the cell surface level, enabling selective uptake by cells expressing CD71 (such as erythroid cells) while leaving other tissues unaffected.
Solution Approach 2:
The patent changes the targeting parameter by using FN3 domains with optimized CD71 binding affinity. This parameter change enables specific recognition and binding to CD71-expressing cells, thereby achieving versatile tissue targeting beyond the liver that is characteristic of lipid nanoparticle delivery.
3Adaptability or versatility
If siRNA is conjugated with FN3 domains, then specific tissue targeting is achieved, but the conjugation process becomes more complex
Solution Approach 1:
The patent segments the delivery system into distinct functional modules: the siRNA payload, the FN3 domain targeting module, and the linker connecting them. This segmentation allows independent optimization of each component and simplifies the overall conjugation process by using standardized connection points.
Solution Approach 2:
The patent creates a composite material by chemically conjugating the FN3 domain protein with the siRNA molecule through a linker. This composite structure combines the protective and targeting functions of the FN3 domain with the therapeutic function of siRNA, achieving both tissue specificity and therapeutic efficacy in a single integrated construct.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FN3-siRNA conjugates effectively target and reduce gene expression in specific tissues, demonstrating high specificity and efficacy in treating various diseases, including Pompe Disease, cancer, and autoimmune disorders.
Implementation Method 1
FN3 domains that specifically bind to CD71, allowing for receptor-mediated internalization and enhanced intracellular delivery
Data Source
AI summary
The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.